GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

1,404.00p
   
  • Change Today:
      14.00p
  • 52 Week High: 1,671.00
  • 52 Week Low: 1,264.00
  • Currency: UK Pounds
  • Shares Issued: 4,089.20m
  • Volume: 4,490,959
  • Market Cap: £57,412m
  • RiskGrade: 129

GSK Overview

We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in commitments to growth and a step-change in performance. We are a company where outstanding people can thrive.
Registrars: Equiniti
Brands: Lucozade, Horlicks, Ribena, Paxil, Seroxat

Key Personnel

CEO: Emma Walmsley
Chief Finance Officer: Julie Brown
Independent Non-Executive Director: Elizabeth (Liz) McKee Anderson
Independent Non-Executive Director: Anne Beal
Independent Non-Executive Director: Harry (Hal) C. Dietz
Independent Non-Executive Director: Vishal Sikka
Non-Executive Chairman: Jonathan Symonds
Senior Independent Non-Executive Director: Charles Bancroft
Non-Executive Dir: Jeannie Lee , Hal Barron , Gavin Screaton, Wendy Becker

Contact Details

Address: 79 New Oxford Street, London, United Kingdom, WC1A 1DG
Phone: +44 (0)20 8047 5000
Website: http://www.gsk.com

Listings

Sector: Pharma and Biotech(LSE)
Index: techMARK, FTSE 100, FTSE 350, FTSE All-Share
Overseas Listings: BATSLON:GSKL, NYSE:GSK
ISIN: GB00BN7SWP63

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,404.00p
Change Today 14.00p
% Change 1.01 %
52 Week High 1,671.00
52 Week Low 1,264.00
Volume 4,490,959
Shares Issued 4,089.20m
Market Cap £57,412m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
48.97% below the market average48.97% below the market average48.97% below the market average48.97% below the market average48.97% below the market average
39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average
Price Trend
1.46% below the market average1.46% below the market average1.46% below the market average1.46% below the market average1.46% below the market average
43.48% above the sector average43.48% above the sector average43.48% above the sector average43.48% above the sector average43.48% above the sector average
Income
73.04% above the market average73.04% above the market average73.04% above the market average73.04% above the market average73.04% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
32.29% below the market average32.29% below the market average32.29% below the market average32.29% below the market average32.29% below the market average
62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average

What The Brokers Say

Strong Buy 3
Buy 3
Neutral 15
Sell 3
Strong Sell 0
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for 01-Jul-2025

Time Volume / Share Price
15:46 215 @ 1,404.00p
15:46 1,250 @ 1,404.28p
15:46 2,500 @ 1,404.40p
15:46 3 @ 1,404.00p
15:46 551 @ 1,404.50p

GSK Key Personnel

CEO Emma Walmsley

Top of Page